StudyFinder

Durvalumab vs Placebo with Stereotactic Body Radiation Therapy in Early Stage NSLC

Status: OPEN TO ACCRUAL

I'm interested

Age:

Healthy Volunteers:

Interventions:

drug: Durvalumab, Modality: Immunotherapy

Conditions:

Lung

Contact(s): Hamilton, Melanie, R - mrhamilton2@vcu.edu

Principal Investigator: Weiss, Elisabeth

Phase: III

IRB Number: HM20018623

System ID: NCT03833154

Back